LETTER TO THE EDITOR

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination

Blood Cancer Journal (2014) 4, e204; doi:10.1038/bcj.2014.24; published online 25 April 2014

The phosphoinositide 3-kinase (PI3K) pathway has a crucial role in tumor progression and drug resistance, including both conventional chemotherapeutics as well as novel agents.¹ Although no mutations have been described in the PI3K/Akt genes in multiple myeloma (MM), it was shown that this pathway is constitutively activated in MM cells and has pleiotropic effects influencing proliferation, drug resistance, angiogenesis and cell adhesion.²

PI3Ks are divided into three subclasses, and of these, class I PI3Ks—p110 α (also known as PIK3CA), p110 β (also known as PIK3CB), p110 γ (also known as PIK3CG) and p110 δ (also known as PIK3CD)—are well described in terms of their role in cancer development and progression.^{1,3} PIK3CA is frequently mutated in solid tumors including carcinoma of the prostate, breast colon and endometrium.^{4,5} However, there have been no reports of cancer-specific mutations in MM.⁶

Recently, a number of potential therapeutics targeting specific PI3K groups or isoforms were developed.^{3,4} Previous studies have indicated that p110 α , p110 β and p110 δ might be potential targets for MM.^{7–9} Although the basic framework of PI3K signaling has been uncovered, the contribution of the different PI3K isoforms is not well understood.⁴ In the current study, we investigated the functional role of class I PI3K isoforms in modulating MM cell trafficking *in vivo* and *in vitro*.

To examine activation of the PI3K/Akt pathway in MM, we first performed gene set enrichment analysis¹⁰ on the gene-expression data set (Shaughnessy *et al.* ref. GSE24080) of patients in different International Staging System stages of MM compared with normal donors;¹¹ and found enrichment of genes related to class I PI3K-activated AKT signaling events. These findings were observed in stage I, II and III MM patients compared with healthy individuals (Figure 1a).

To study the role of each isoform (p110 α , β , γ , and δ) in regulating MM cell survival and trafficking *in vivo* and *in vitro*, the expression of PI3K isoforms was examined in a panel of eight MM cell lines showing different levels of expression of PI3K isoforms with only MM.1S expressing all isoforms (Figure 1b). Thus, MM.1S-GFP⁺/Luc⁺ was infected with lentivirus-mediated small hairpin RNAs targeting the different PI3K isoforms. Stable cell lines were generated, and efficiency of knockdown for each isoform was confirmed by reverse transcription quantitative PCR (Figure 1c). Specificity of knockdown was demonstrated by immunoblotting in cell lines using specific antibodies against each isoform (Figure 1d). Then, we evaluated the effect of each isoform on PI3K–Akt signaling in MM cells in the context of primary MM bone marrow mesenchymal stromal cells (BM-MSCs) and found inhibition of BM-MSC-dependent induction of phospho(p)-Akt in MM cells with all PI3K isoforms silenced in the tumor clone (Figure 1e). Although p110 α , β , and δ showed a modest reduction in cell survival *in vitro* (Figure 1f), cell cycle analysis revealed no significant difference on cell cycle distribution patterns (Supplementary Figure 1). We next performed adhesion assay of MM cells to primary MM-derived BM-MSCs; and found that by silencing each of class I PI3K isoforms, MM cells inhibited their

adhesion properties, with the p110 β and p110 δ knockdown being the most effective (53% reduction and 47% reduction, respectively; $P < 0.001$, $P < 0.01$; Figure 1g).

To test the effect of the different p110 isoforms on MM tumor progression *in vivo*, SCID-Bg mice were injected with MM cells silenced for p110 α , β , γ and δ , and tumor development was monitored by bioluminescence imaging. Scramble-infected cells were used as control. In consistent with *in vitro* data demonstrating that the most significant changes were observed for adhesion of MM cells to BM-MSCs in p110 β and p110 δ knockdown cells, tumor progression was significantly lower in p110 β - and p110 δ -knockdown cell-injected mice compared with scramble cell-injected mice ($P < 0.05$); whereas tumor growth observed in p110 α - and p110 γ -knockdown cell-injected mice was similar to control mice (Figures 2a and b). We speculate that this might be due to markedly decreased tumor cell growth triggered by MM cell adhesion to BM-MSCs, as the adhesion of MM cells to BM-MSCs activates many pathways and has a vital role in MM pathogenesis and disease progression.¹² We further confirmed that tumor cells showed knockdown for each p110 isoform, as demonstrated *ex vivo* on tumor cells harvested from each cohort of mice (Figure 2c). Mice were followed until the development of hind limb paralysis or death, and Kaplan–Meier analysis was performed showing prolonged survival in all groups except p110 α mice (p110 β and p110 γ , $P < 0.05$; p110 δ , $P < 0.001$; Figure 2d). Despite similar tumor burden observed between p110 γ mice and scramble control-injected mice, mice injected with p110 γ knockdown cells had improved survival compared with control mice. This might be due to the different extent of tumor involvement of various organs¹³ between the two groups, thus explaining the differences in survival.

Interestingly, our data indicate that p110 α is not critical for the survival of MM cells *in vivo*. Unlike most solid tumor malignancies, where PI3KCA (p110 α) mutation is the leading cause of activation of this pathway and is the target of many therapeutic agents in development,³ there have been no reports of this specific mutations in MM.⁶ Moreover, it was shown that unlike wild-type p110 α , overexpression of the wild-type p110 β , p110 γ and p110 δ is sufficient to induce an oncogenic transformation of fibroblasts in cell culture.¹⁴

In this study, p110 β was highly expressed in all MM cell lines, whereas only a minor subset expressed p110 δ at the protein level (Figure 1b), which is consistent with a recent report⁹ showing expression of p110 β in 38 MM cell lines in comparison to the detectable expression of p110 δ in only 4 cell lines. In addition, another study⁸ reported similar findings in cell lines showing lack of p110 δ expression in most MM cell lines. Of note, we found discrepancies in p110 δ expression in cell lines between our study and prior published studies but our data was confirmed in the Cancer Cell Line Encyclopedia data at the mRNA level (data not shown).¹⁵ Importantly, Ikeda *et al.*⁸ evaluated p110 δ levels in patient samples and detected its expression in all 24 MM patients. This may provide a clinical rationale for targeting p110 δ despite the lack of expression of p110 δ in MM cell lines.

Overall, our data suggest that, in contrast with solid tumors, MM may be more dependent on PI3K p110 β and p110 δ and less dependent on PI3K α , and these may be the focus of drug development in this hematological malignancy.

Figure 2. (Continued)

Figure 1. The role of class I PI3K-mediated Akt signaling in MM. (a) Gene set enrichment analysis software analyzed functionally related genes in class I-mediated Akt activation with statistically significant enrichment (false-discovery rate q -values < 0.25 ; < 0.25 is considered significant), using gene-expression data set (GSE24080). Plots show enrichment results for the gene set (left, stage I MM vs normal subjects; middle, stage II MM vs normal subject; right, stage III MM vs normal subjects). (b) Baseline expression of the different PI3K isoforms (p110 α , β , γ and δ) in MM cell lines was detected by immunoblotting using isoform-specific antibodies. MM tumor cells (MM.1S-GFP⁺/luc⁺) were infected with lentivirus-mediated small hairpin (sh)RNA. Reverse transcription quantitative PCR (c) and immunoblotting (d) were performed to show infection efficiency and isoform specificity, respectively. Scramble and knockdown tumor cells (p110 α , β , γ and δ) were cocultured with BMSCs overnight, and MM cells were then separated from the BMSCs, lysed and whole-cell lysates were subjected to immunoblotting (e) with Akt and P-Akt (Thr308 and Ser473), which shows decreased phosphorylation of Akt in knockdown cells. The effects of inhibition of PI3K isoforms by shRNAs on cell survival were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (f). Adhesion assay (g) was performed to show the ability of knockdown cells to adhere to BMSCs after 2 h of incubation.

Figure 2. Knockdown of PI3K isoforms regulates tumor progression and survival *in vivo*. MM.1S-GFP⁺/luc⁺ tumor cell lines (Scr, p110 α , β , γ and δ) were injected intravenously into SCID-Bg mice and tumor growth was assessed by *in vivo* bioluminescence imaging (BLI). (a) Representative BLI of each group in different time points is shown. (b) Quantification of BLI signals demonstrated that p110 β and δ mice showed significant reduction in tumor growth ($P<0.05$) compared with scramble mice. (c) Reverse transcription quantitative PCR was performed on tumor cells that were harvested from hind leg bones of animals by bone marrow flushing. (d) Survival of mice was evaluated until complete hind limb paralysis or death using Kaplan–Meier curves. Compared with scramble mice, all groups except p110 α showed prolonged survival (p110 β and p110 γ , $P<0.05$; p110 δ , $P<0.001$).

CONFLICT OF INTEREST

IMG is on the advisory board for Onyx, BMS and Celgene, and receives research lab support from Genzyme and BMS. The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by R01CA154648.

AUTHOR CONTRIBUTIONS

IS: designed and performed the research, analyzed the data and wrote the manuscript; MM, YM, SVG, BT, FA, YZ, PM, AS, AKA and AMR: performed the research and analyzed the data; IMG: supervised the study and wrote the manuscript.

I Sahin¹, M Moschetta¹, Y Mishima¹, SV Glavey¹, B Tsang¹, F Azab^{1,2}, S Manier¹, Y Zhang¹, P Maiso¹, A Sacco¹, AK Azab^{1,2}, AM Rocco¹ and IM Ghobrial¹

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA and

²Cancer Biology Division, Department of Radiation Oncology, School of Medicine, Washington University in St Louis, St Louis, MO, USA
E-mail: irene_ghobrial@dfci.harvard.edu

REFERENCES

- Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. *Nat Rev Clin Oncol* 2013; **10**: 143–153.
- Harvey RD, Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. *Future Oncol* 2007; **3**: 639–647.
- Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. *J Clin Oncol* 2010; **28**: 1075–1083.
- Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. *Nat Rev Mol Cell Biol* 2010; **11**: 329–341.
- Zhao L, Vogt PK. Class I. PI3K in oncogenic cellular transformation. *Oncogene* 2008; **27**: 5486–5496.
- Ismail SI, Mahmoud IS, Msallam MM, Sughayer MA. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. *Leuk Res* 2010; **34**: 824–826.
- Glauer J, Pletz N, Schon M, Schneider P, Liu N, Ziegelbauer K *et al*. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma *in vitro* and *in vivo*. *Blood Cancer J* 2013; **3**: e141.
- Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H *et al*. PI3K/p110 δ is a novel therapeutic target in multiple myeloma. *Blood* 2010; **116**: 1460–1468.
- Munugalavada V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G *et al*. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. *Oncogene* 2013; **33**: 316–325.

- 10 Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA *et al*. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 2005; **102**: 15545–15550.
- 11 Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T *et al*. PID: the Pathway Interaction Database. *Nucleic Acids Res* 2009; **37**(Database issue): D674–D679.
- 12 Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. *Blood Rev* 2010; **24**(Suppl 1): S5–S11.
- 13 Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. *Cancer Res* 1993; **53**: 1392–1396.
- 14 Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proc Natl Acad Sci USA* 2006; **103**: 1289–1294.
- 15 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S *et al*. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012; **483**: 603–607.

This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0/>

Supplementary Information accompanies this paper on Blood Cancer Journal website (<http://www.nature.com/bcj>)